286 related articles for article (PubMed ID: 9322882)
1. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
2. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
Wagner A; Hempel G; Boos J
Anticancer Drugs; 1997 Jun; 8(5):419-31. PubMed ID: 9215603
[TBL] [Abstract][Full Text] [Related]
3. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
4. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.
Williams ML; Wainer IW
Curr Pharm Des; 1999 Aug; 5(8):665-72. PubMed ID: 10469897
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of ifosfamide.
Furlanut M; Franceschi L
Oncology; 2003; 65 Suppl 2():2-6. PubMed ID: 14586139
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
9. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
11. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
12. Ecotoxicity and genotoxicity of cyclophosphamide, ifosfamide, their metabolites/transformation products and their mixtures.
Česen M; Eleršek T; Novak M; Žegura B; Kosjek T; Filipič M; Heath E
Environ Pollut; 2016 Mar; 210():192-201. PubMed ID: 26735164
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
14. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
15. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
[TBL] [Abstract][Full Text] [Related]
17. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
18. [Tests of biodegradation of cytostatics cyclophosphamide and ifosfamide using the Closed Bottle Test (OECD 301 D)].
Kümmerer K; Steger-Hartmann T; Baranyai A; Bürhaus I
Zentralbl Hyg Umweltmed; 1996 Feb; 198(3):215-25. PubMed ID: 9376051
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity during ifosfamide treatment in children.
Di Cataldo A; Astuto M; Rizzo G; Bertuna G; Russo G; Incorpora G
Med Sci Monit; 2009 Jan; 15(1):CS22-5. PubMed ID: 19114973
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide--pharmacologic overview.
Sarosy G
Semin Oncol; 1989 Feb; 16(1 Suppl 3):2-8. PubMed ID: 2649983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
